SK282452B6 - Kombinovaný farmaceutický prostriedok na liečbu ľudských nádorových buniek, použitie O6-benzylguanínu a temozolomidu na jeho prípravu a farmaceutický kit - Google Patents

Kombinovaný farmaceutický prostriedok na liečbu ľudských nádorových buniek, použitie O6-benzylguanínu a temozolomidu na jeho prípravu a farmaceutický kit Download PDF

Info

Publication number
SK282452B6
SK282452B6 SK892-95A SK89295A SK282452B6 SK 282452 B6 SK282452 B6 SK 282452B6 SK 89295 A SK89295 A SK 89295A SK 282452 B6 SK282452 B6 SK 282452B6
Authority
SK
Slovakia
Prior art keywords
temozolomide
atase
benzylguanine
treatment
cells
Prior art date
Application number
SK892-95A
Other languages
English (en)
Slovak (sk)
Other versions
SK89295A3 (en
Inventor
John Colin Baer
Azadeh Alison Freeman
Edward Stuart Newlands
Amanda Jean Watson
Joseph Anthony Rafferty
Geoffrey Paul Margison
Original Assignee
Cancer Research Campaign Technology Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Campaign Technology Limited filed Critical Cancer Research Campaign Technology Limited
Publication of SK89295A3 publication Critical patent/SK89295A3/sk
Publication of SK282452B6 publication Critical patent/SK282452B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
SK892-95A 1993-01-14 1994-01-13 Kombinovaný farmaceutický prostriedok na liečbu ľudských nádorových buniek, použitie O6-benzylguanínu a temozolomidu na jeho prípravu a farmaceutický kit SK282452B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US475493A 1993-01-14 1993-01-14
PCT/GB1994/000065 WO1994015615A1 (en) 1993-01-14 1994-01-13 Potentiation of temozolomide in human tumour cells

Publications (2)

Publication Number Publication Date
SK89295A3 SK89295A3 (en) 1996-06-05
SK282452B6 true SK282452B6 (sk) 2002-02-05

Family

ID=21712364

Family Applications (1)

Application Number Title Priority Date Filing Date
SK892-95A SK282452B6 (sk) 1993-01-14 1994-01-13 Kombinovaný farmaceutický prostriedok na liečbu ľudských nádorových buniek, použitie O6-benzylguanínu a temozolomidu na jeho prípravu a farmaceutický kit

Country Status (20)

Country Link
EP (2) EP0679086A1 (ja)
JP (1) JPH08505615A (ja)
KR (1) KR100352046B1 (ja)
CN (1) CN1277541C (ja)
AU (1) AU5838494A (ja)
CA (1) CA2153775C (ja)
CZ (1) CZ286550B6 (ja)
FI (1) FI953423A (ja)
HU (1) HUT72665A (ja)
IL (1) IL108328A (ja)
MX (1) MX9400434A (ja)
MY (1) MY116474A (ja)
NO (1) NO952781L (ja)
PL (1) PL175842B1 (ja)
RU (1) RU2148401C1 (ja)
SK (1) SK282452B6 (ja)
TW (1) TW414710B (ja)
UA (1) UA29466C2 (ja)
WO (1) WO1994015615A1 (ja)
ZA (1) ZA94248B (ja)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731304A (en) * 1982-08-23 1998-03-24 Cancer Research Campaign Technology Potentiation of temozolomide in human tumour cells
US5942247A (en) * 1996-07-31 1999-08-24 Schering Corporation Method for treating pediatric high grade astrocytoma including brain stem glioma
US5939098A (en) * 1996-09-19 1999-08-17 Schering Corporation Cancer treatment with temozolomide
WO2000033823A2 (en) * 1998-12-07 2000-06-15 Schering Corporation Methods of using temozolomide in the treatment of cancers
US6251886B1 (en) 1998-12-07 2001-06-26 Schering Corporation Methods of using temozolomide in the treatment of cancers
US6635677B2 (en) 1999-08-13 2003-10-21 Case Western Reserve University Methoxyamine combinations in the treatment of cancer
US6465448B1 (en) 1999-08-13 2002-10-15 Case Western Reserve University Methoxyamine potentiation of temozolomide anti-cancer activity
CA2476494C (en) * 2002-02-22 2010-04-27 Schering Corporation Pharmaceutical formulations of antineoplastic agents, in particular temozolomide, processes of making and using the same
WO2003101474A1 (en) * 2002-05-31 2003-12-11 Transmolecular, Inc. Combination chemotherapy with chlorotoxin
CN100350974C (zh) * 2005-02-03 2007-11-28 山东蓝金生物工程有限公司 一种抗癌药物组合物
CN100350975C (zh) * 2005-02-03 2007-11-28 山东蓝金生物工程有限公司 抗癌药物组合物
CN100402091C (zh) * 2005-02-03 2008-07-16 山东蓝金生物工程有限公司 一种抗癌药物组合物
CN100431605C (zh) * 2005-02-03 2008-11-12 山东蓝金生物工程有限公司 一种抗癌药物组合物
GB0502573D0 (en) * 2005-02-08 2005-03-16 Topotarget As Therapeutic compounds
WO2008022535A1 (fr) * 2006-08-09 2008-02-28 Tian Jin Tasly Group Co., Ltd. Composition pharmaceutique pour traiter le gliome du cerveau, son procédé et sa préparation pharmaceutique
JP2011520914A (ja) 2008-05-15 2011-07-21 トランスモレキュラー， インコーポレイテッド 転移腫瘍の処置
HUE034119T2 (en) 2010-02-04 2018-01-29 Morphotek Inc Chlorotoxin polypeptides and conjugates and their use
WO2011142858A2 (en) 2010-05-11 2011-11-17 Fred Hutchinson Cancer Research Center Chlorotoxin variants, conjugates, and methods for their use
CN103169664B (zh) * 2011-12-25 2015-04-22 复旦大学 一种rgd肽修饰的双层载药纳米粒及其制备方法
BR112015013525A2 (pt) 2012-12-10 2017-11-14 Hutchinson Fred Cancer Res método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof

Also Published As

Publication number Publication date
UA29466C2 (uk) 2000-11-15
IL108328A0 (en) 1994-04-12
CZ179795A3 (en) 1996-04-17
MX9400434A (es) 1994-07-29
CN1277541C (zh) 2006-10-04
CA2153775C (en) 2000-11-14
ZA94248B (en) 1994-07-13
PL175842B1 (pl) 1999-02-26
FI953423A (fi) 1995-08-23
TW414710B (en) 2000-12-11
RU2148401C1 (ru) 2000-05-10
MY116474A (en) 2004-02-28
PL309915A1 (en) 1995-11-13
WO1994015615A1 (en) 1994-07-21
NO952781L (no) 1995-09-13
HUT72665A (en) 1996-05-28
EP0679086A1 (en) 1995-11-02
AU5838494A (en) 1994-08-15
CN1117711A (zh) 1996-02-28
EP0922458A1 (en) 1999-06-16
HU9502117D0 (en) 1995-09-28
KR100352046B1 (ko) 2003-09-03
IL108328A (en) 2010-05-31
SK89295A3 (en) 1996-06-05
NO952781D0 (no) 1995-07-13
CZ286550B6 (cs) 2000-05-17
CA2153775A1 (en) 1994-07-21
FI953423A0 (fi) 1995-07-13
JPH08505615A (ja) 1996-06-18
KR960700063A (ko) 1996-01-19

Similar Documents

Publication Publication Date Title
SK282452B6 (sk) Kombinovaný farmaceutický prostriedok na liečbu ľudských nádorových buniek, použitie O6-benzylguanínu a temozolomidu na jeho prípravu a farmaceutický kit
Ishikawa et al. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts
AU714057B2 (en) A pharmaceutical composition containing N-phosphonoglycine derivatives for inhibiting the growth of viruses and cancers
US6552059B2 (en) Pharmaceutical composition for and method of treating leukemia
EP0821586B1 (en) A pharmaceutical composition containing benzimidazole for inhibiting the growth of cancers
US5731304A (en) Potentiation of temozolomide in human tumour cells
EP2818170B1 (en) N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridin yl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer
US5576316A (en) Method for inhibiting tumor growth rate using creatine or creatine analogs
JP2016519684A (ja) 準最適に投与された薬物療法の有効性を改善するための及び／又は副作用を低減するための方法および組成物
KR20080004495A (ko) 암을 치료하기 위한 조합물, 방법 및 조성물
US6906091B2 (en) Method of cancer treatment
WO2002045717A1 (en) Lometrexol combination therapy
KR19990036138A (ko) 암 성장을 억제하기 위한 플루코나졸의 용도
JPH11511136A (ja) 癌の成長を阻害するためのグリセオフルビンの使用
KR19990036136A (ko) 암 성장을 억제하기 위한 1ｈ-1,2,4-트리아졸 유도체의 용도
MXPA98000944A (es) Uso de derivados de 1h-1,2,4-triazol para inhibirel crecimiento de canceres
CZ323597A3 (cs) Farmaceutický prostředek obsahující N-chlorfenylkarbamáty a N-chlorfenylthiocarbamaty pro inhibici růstu virů a karcinom
US11583509B2 (en) Compound for treating cancer and diabetes
CA2672716C (fr) Nouvelle utilisation therapeutique pour le traitement des leucemies
EP2207548A1 (en) Breast cancer therapy
AU721950B2 (en) Potentiation of temozolomide in human tumour cells
CA2444334A1 (fr) Associations pharmaceutiques a base de derives de pyridoindolone et d'agents anticancereux
EP2711008A1 (en) N6,N6-dimethyladenosine for use in treating or preventing primary and metastatic breast cancer
Dhingra et al. Expanding horizons in the treatment of mantle cell lymphoma: Ibrutinib a novel BTK-targeting inhibitor
EP2711009A1 (en) Compounds for use in treating or preventing primary and metastatic breast and prostate cancer